

Doctoral Dissertation and Prior Research Experience *Graduate Research at the University California, Irvine, August 2012–May 2018. Supervised by Prof. Jennifer Prescher:*

Over the course of my graduate work I have developed the first example of multicomponent bioluminescence imaging with synthetic probes and gained broad experience in the areas of chemical biology and reaction methodology. These efforts combined my skills in chemical synthesis, biological assay development, and computer programming. My work has wide implications in the fields of imaging and protein engineering.

Expanding the imaging toolkit

Genetically-encoded optical reporters have revolutionized our understanding of biological systems. These tools, namely fluorescent proteins, allow researchers to track multiple targets over extended periods of time in cellulo. However, the transition of fluorescent probes in vivo, to multicellular clinical models, has been hampered by the opacity of tissue and its propensity for autofluorescence. A complementary imaging technology, bioluminescence, does not suffer from these complications because it does not require excitation light (Rathbun, C. M. and Prescher, J. A. *Biochemistry*, **2017**, 56, 5178.). Thus, the technique is exquisitely sensitive with the ability to see as few as ten cells and is often more suitable for imaging in thick tissues and entire organisms. Bioluminescence relies on luciferase enzymes that catalyze the oxidation of small-molecule substrates (luciferins), releasing photons of light in the process (Fig. ??). Unfortunately, the optimal luciferases for in vivo use rely on the same small molecule luciferin, precluding studies of more than one feature or cell type at a time.

To address this issue, I developed and analyzed a number of new luciferin probes, and created a selection platform to find mutually orthogonal luciferases and luciferins for multicomponent imaging. In contrast to the spectroscopic resolution of fluorescent tools, these probes were designed to exhibit substrate resolution. Since red light is the only color capable of penetrating tissue, spectral resolution in vivo is difficult to achieve. Thus, I resolved to take advantage of the molecular component of bioluminescence imaging to develop exclusively selective luciferin-luciferase pairs.





Figure 2. A) Strategy for developing orthogonal bioluminescent probes. B) A top pair isolated via parallel screening.

proven general for these analogs as well, providing a benchmark for light emission before mutant luciferases are developed.



something else here??

Figure 1. A) Cobalamin acts as a quenching and localization moiety to guide a fluorescent probe to an RNA transcript of interest. When unbound, fluorescence is quenched. In the presence of RNA tagged with the cobalamin aptamer, fluorescence is restored.

Brominated luciferins are versatile bioluminescent probes

My strategy for mutually selective probes relied on synthesizing small molecule luciferin analogs and screening them against libraries of functional mutant luciferases. I initially focused on development of minimally perturbed luciferin probes. We rationalized that bromination of the luciferin core might perturb binding to the wildtype enzyme, yet retain inherent light-emitting ability of the molecule. Directed evolution could then be used to restore light emission. To verify this, I developed a chemiluminescence assay to test the relative light-emitting abilities of our luciferin analogs (Figure 1B). Gratifyingly, the brominated probes showed robust emission, indicating that these molecules had the potential to be capable emitters (Figure 1C). Additionally, I have shown that cross-coupling reactions can be used to derivatize the brominated luciferins, producing a variety of modified scaffolds in a divergent manner. This work resulted in a publication in *ChemBioChem* (Steinhardt, R. C. *et al.*, *ChemBioChem*, **2016**, 18, 96.). In addition to the brominated variants, my colleagues and I synthesized a wide variety of modified luciferins analogs ranging from subtle electronic modifications, to large steric perturbations. The chemiluminescence assay has

Orthogonal Luciferase-luciferin pairs for bioluminescence imaging

Next, we sought to identify luciferase mutants that selectively utilized our luciferin analogs. We designed and generated a range of functional luciferases that reflected a variety of mutations about the active site. Combining molecules and enzymes, we tested 20 luciferins with 207 mutant luciferases (Fig. 2). The screening experiment generated 4,140 enzyme-substrate combinations, and thus a potential for more than 4 million possible sets of two substrates and two enzymes. Since it would be impractical to evaluate all of these combinations manually, I first derived a mathematical quantification of orthogonality to score each potential pairing. Next, I wrote a supercomputer algorithm to search this dataset in a matter of minutes for the highest-scoring pairs. The software provided a ranked list of mutually orthogonal enzyme-substrate pairs that were biochemically verified. A top hit from this list is shown in Figure 2B. Each enzyme exhibited greater than ten-fold preference for its matched substrate. Resolution was maintained when these probes were moved into mouse models, highlighting the speed and accuracy of our approach (Figure 3A). As a next step, I have been searching the data sets for not just pairs of bioluminescent tools, but triplet and quadruplet sets of orthogonal probes. This would enable visualization of three or more populations of interest simultaneously. However, the problem becomes much more complex due to the increase in possible pairings (Fig. 2A). Using my algorithm, I have identified 6,171 possible sets of orthogonal triplets, several of which have been verified in bacterial lysate. This work resulted in publications in JACS, and ACS Central Science (Rathbun, C. M. *et al.*, *J. Am. Chem. Soc.*, **2017**, 139, 2351. and Rathbun, C. M. *et al.*, *ACS Cent. Sci.*, **2017**, 3, 1254.). We hope to use these tools to monitor the locations of cancer cells and the immune system throughout disease progression. Collectively, our orthogonal pairs will enable a variety of multicomponent, in vivo imaging studies, and my screening techniques and computer algorithm will enable advances in other areas of chemical biology.

Expanding the scope of multicomponent imaging

My most recent work focused on increasing the practicality of these tools for preclinical in vivo imaging. The major drawbacks of our substrate resolution approach included temporal resolution and background emission. I addressed these issues by utilizing traditional spectral unmixing algorithms to deconvolute substrate signals mathematically. This enabled sequential imaging of substrates, and the ability to resolve smaller numbers of cells. With a top orthogonal pair we “unmixed” gradients of mutant luciferases in bacterial lysate and resolved mixtures of these mutants in mouse tumor models. Tumors were implanted in mice with varying mixtures of mammalian cells expressing our top probes. Luciferin substrates were sequentially administered and images were acquired between injections. The images were then “unmixed” and overlaid (Fig. 4). We are currently applying this technique to track cells involved in metastasis *in vivo*.




Figure 4: Mouse unmixing.




Figure 3. Mutually orthogonal pairs enable multi-component imaging in mouse models.

Previous work in transition metal catalysis methodology

I spent the first year and a half of my graduate work in the lab of Professor Vy Dong. During this time, I sought new, streamlined methods of carbohydrate synthesis. We developed a new method of selectively acylating sugars via copper catalysis (Chen, I. H. *et al.*, *Chem. Eur. J.*, **2014**, 20, 5013.). Our catalysts could distinguish between three similar alcohols moieties to acylate at a set position, depending on the ligand used. This method proved general for a variety of sugar scaffolds containing cis diols.